1. Home
  2. GLU vs ELTX Comparison

GLU vs ELTX Comparison

Compare GLU & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GLU
  • ELTX
  • Stock Information
  • Founded
  • GLU 2004
  • ELTX 2011
  • Country
  • GLU United States
  • ELTX United States
  • Employees
  • GLU N/A
  • ELTX N/A
  • Industry
  • GLU Finance/Investors Services
  • ELTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • GLU Finance
  • ELTX Health Care
  • Exchange
  • GLU Nasdaq
  • ELTX Nasdaq
  • Market Cap
  • GLU 99.4M
  • ELTX 121.7M
  • IPO Year
  • GLU N/A
  • ELTX N/A
  • Fundamental
  • Price
  • GLU $17.65
  • ELTX $8.09
  • Analyst Decision
  • GLU
  • ELTX Strong Buy
  • Analyst Count
  • GLU 0
  • ELTX 2
  • Target Price
  • GLU N/A
  • ELTX $9.50
  • AVG Volume (30 Days)
  • GLU 12.4K
  • ELTX 48.3K
  • Earning Date
  • GLU 01-01-0001
  • ELTX 08-12-2025
  • Dividend Yield
  • GLU 8.60%
  • ELTX N/A
  • EPS Growth
  • GLU N/A
  • ELTX N/A
  • EPS
  • GLU 0.62
  • ELTX N/A
  • Revenue
  • GLU N/A
  • ELTX N/A
  • Revenue This Year
  • GLU N/A
  • ELTX N/A
  • Revenue Next Year
  • GLU N/A
  • ELTX N/A
  • P/E Ratio
  • GLU $22.50
  • ELTX N/A
  • Revenue Growth
  • GLU N/A
  • ELTX N/A
  • 52 Week Low
  • GLU $11.61
  • ELTX $3.70
  • 52 Week High
  • GLU $15.40
  • ELTX $9.99
  • Technical
  • Relative Strength Index (RSI)
  • GLU 68.62
  • ELTX 62.14
  • Support Level
  • GLU $17.38
  • ELTX $7.76
  • Resistance Level
  • GLU $17.77
  • ELTX $8.94
  • Average True Range (ATR)
  • GLU 0.20
  • ELTX 0.37
  • MACD
  • GLU 0.05
  • ELTX -0.03
  • Stochastic Oscillator
  • GLU 100.00
  • ELTX 51.09

About GLU Gabelli Global Utility of Beneficial Ownership

Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.

Share on Social Networks: